Angiopoietin 2 expression is significantly correlated with higher Gleason score, angiogenesis, metastases, and cancer-specific survival in prostate cancer, suggesting it is an important regulator of angiogenesis in this malignancy.
Answers are grounded in this paper and cite their sources.
Angiopoietin-2 expression may aid risk stratification in prostate cancer; leaves open its value as a prognostic biomarker or therapeutic target.
BACKGROUND: In several malignant tissues, the angiopoietins are principal regulators of vascular growth and regression, but in normal prostate and prostate tumors the role of the angiopoietins is unknown. METHODS: Angiopoietin (ang) 1 and 2 were immunolocalized in TUR-diagnosed prostate tumors with long follow-up and the expression was related to vascular density and clinicopathological variables. RESULTS: Ang 1 was strongly expressed in the basal epithelial cell layer in non-malignant tissue, whereas tumors had lower levels localized to the epithelial cells. A weak ang 2 immunoreaction was observed in non-malignant tissue and in low to intermediate Gleason score (GS) tumors, with a similar expression pattern. However, most high GS tumors showed an intense ang 2 staining. Ang 2 was significantly correlated to GS, density of endoglin stained blood vessels, metastases, and to cancer specific survival. CONCLUSIONS: We conclude that ang 2 probably is an important regulator of angiogenesis in prostate cancer.
No takes yet. Share an insight, caveat, or question.
Lind et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: